Efficacy of ivabradine in combination with beta-blockers vs up-titration of beta-blockers in daily practice

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivabradine (Primary)
Indications Angina pectoris
Focus Therapeutic Use
Acronyms CONTROL-2
Sponsors Servier

Most Recent Events

09 Mar 2018 New trial record
05 Mar 2018 Primary endpoin (Change in heart rate during the 16-week treatment period)t has been met as per the results published in the Advances in Therapy
05 Mar 2018 Primary endpoint (Number of angina attacks with standard therapy vs ivabradine) has been met as per the results published in the Advances in Therapy

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight